IPF Antifibrotic Therapy

Idiopathic pulmonary fibrosis (IPF) was long considered an untreatable disease with a median survival of 3-5 years from diagnosis — worse than many cancers. For decades, the standard approach was immunosuppressive therapy (prednisone plus azathioprine), based on the incorrect assumption that IPF was driven by chronic inflammation. The PANTHER-IPF trial (2012) provided the critical negative signal: the triple-therapy arm of prednisone, azathioprine, and N-acetylcysteine was stopped early due to increased mortality (8% vs 2%), hospitalizations, and serious adverse events compared to placebo. This landmark finding not only halted a harmful treatment but fundamentally reframed IPF pathogenesis from inflammatory to fibroproliferative, directing research toward antifibrotic rather than anti-inflammatory targets.

Pirfenidone became the first antifibrotic approved for IPF based on the CAPACITY (004/006) and ASCEND trials. The ASCEND trial (2014) demonstrated that pirfenidone reduced the proportion of patients with ≥10% decline in FVC by 47.9% at 52 weeks, with a pooled analysis with CAPACITY suggesting a 48% reduction in all-cause mortality. The INPULSIS 1 and 2 trials simultaneously established nintedanib (a tyrosine kinase inhibitor targeting FGFR, PDGFR, and VEGFR) as an equally effective antifibrotic, reducing the annual rate of FVC decline by approximately 50% versus placebo. For the first time, IPF patients had two disease-modifying therapies proven to slow progression, transforming a previously nihilistic diagnosis into a manageable chronic disease. The two agents worked through distinct mechanisms, offering treatment options despite similar overall efficacy.

The concept of progressive fibrosing interstitial lung disease (PF-ILD) — recognizing that non-IPF ILDs can also develop a progressive, fibrotic phenotype — dramatically expanded the indication for antifibrotic therapy. The INBUILD trial (2019) demonstrated that nintedanib reduced FVC decline in PF-ILDs regardless of underlying diagnosis (systemic sclerosis-ILD, hypersensitivity pneumonitis, autoimmune ILD, unclassifiable ILD), with an effect size similar to IPF trials. The SENSCIS trial showed nintedanib's efficacy specifically in systemic sclerosis-associated ILD. These trials established the principle that fibrosis progression, regardless of its initial trigger, responds to antifibrotic therapy — a paradigm shift from disease-specific to phenotype-based treatment. Combination antifibrotic therapy (pirfenidone plus nintedanib) has been explored in small studies with acceptable safety, though definitive efficacy data are pending.

The ATS/ERS/JRS/ALAT 2022 updated IPF guidelines conditionally recommend both pirfenidone and nintedanib for patients with IPF, regardless of disease severity. NICE and European guidelines similarly endorse antifibrotic therapy with monitoring for side effects (GI for nintedanib, photosensitivity/hepatotoxicity for pirfenidone). The 2022 ATS/ERS PF-ILD guideline extension recommends nintedanib for progressive non-IPF fibrosing ILDs when progression occurs despite appropriate management of the underlying disease. Guidelines emphasize multidisciplinary team (MDT) discussion for diagnosis, early referral for transplant assessment, and comprehensive supportive care including pulmonary rehabilitation, oxygen therapy, and palliative care alongside antifibrotic treatment.

IPF and progressive fibrosing ILD management in 2025-2026 centers on early diagnosis and prompt antifibrotic initiation. Biomarker research (KL-6, SP-D, MUC5B promoter variant rs35705950) is improving early detection and prognostication. Inhaled pirfenidone formulations are in development to improve tolerability by reducing systemic GI side effects. Novel antifibrotic targets in clinical trials include pentraxin-2 (PRM-151), autotaxin inhibitors, and galectin-3 inhibitors. Combination antifibrotic strategies remain an active area of investigation. Lung transplantation remains the only intervention that improves survival, with IPF now the most common indication for transplant in many centers. The extension of antifibrotic principles to non-IPF progressive ILDs has approximately tripled the eligible patient population, making ILD a major subspecialty focus in pulmonary medicine.